- Home
- MPB vs HUMA Comparison
MPB vs HUMA Comparison
Compare MPB & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- HUMA
- Stock Information
- Founded
- MPB 1868
- HUMA 2004
- Country
- MPB United States
- HUMA United States
- Employees
- MPB N/A
- HUMA N/A
- Industry
- MPB Major Banks
- HUMA Biotechnology: Pharmaceutical Preparations
- Sector
- MPB Finance
- HUMA Health Care
- Exchange
- MPB Nasdaq
- HUMA Nasdaq
- Market Cap
- MPB 691.1M
- HUMA 250.2M
- IPO Year
- MPB N/A
- HUMA N/A
- Fundamental
- Price
- MPB $31.64
- HUMA $1.79
- Analyst Decision
- MPB Buy
- HUMA Strong Buy
- Analyst Count
- MPB 2
- HUMA 8
- Target Price
- MPB $34.50
- HUMA $10.88
- AVG Volume (30 Days)
- MPB 89.6K
- HUMA 3.1M
- Earning Date
- MPB 10-22-2025
- HUMA 11-07-2025
- Dividend Yield
- MPB 2.55%
- HUMA N/A
- EPS Growth
- MPB N/A
- HUMA N/A
- EPS
- MPB 2.30
- HUMA N/A
- Revenue
- MPB $191,454,000.00
- HUMA $818,000.00
- Revenue This Year
- MPB $24.57
- HUMA N/A
- Revenue Next Year
- MPB $12.23
- HUMA $1,619.38
- P/E Ratio
- MPB $13.65
- HUMA N/A
- Revenue Growth
- MPB 13.34
- HUMA N/A
- 52 Week Low
- MPB $22.50
- HUMA $1.15
- 52 Week High
- MPB $33.87
- HUMA $6.77
- Technical
- Relative Strength Index (RSI)
- MPB 74.26
- HUMA 56.84
- Support Level
- MPB $29.94
- HUMA $1.45
- Resistance Level
- MPB $30.44
- HUMA $1.53
- Average True Range (ATR)
- MPB 0.63
- HUMA 0.10
- MACD
- MPB 0.05
- HUMA 0.05
- Stochastic Oscillator
- MPB 99.72
- HUMA 82.00
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.